Science & Technology
Fri, September 3, 2010Thu, September 2, 2010Wed, September 1, 2010Tue, August 31, 2010Mon, August 30, 2010Fri, August 27, 2010Thu, August 26, 2010Wed, August 25, 2010Tue, August 24, 2010Mon, August 23, 2010Fri, August 20, 2010Thu, August 19, 2010Wed, August 18, 2010Tue, August 17, 2010Mon, August 16, 2010Sat, August 14, 2010Fri, August 13, 2010Thu, August 12, 2010Simulations Plus Releases GastroPlusa" Version 7.0
Published in Science and Technology on Tuesday, August 24th 2010 at 5:10 GMT by Market Wire
LANCASTER, Calif.--([ BUSINESS WIRE ])--[ Simulations Plus, Inc. ] (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of Version 7.0 of [ GastroPlus ], the industrya™s gold standard software for the simulation of drug absorption, pharmacokinetics, and pharmacodynamics.
"Version 7.0 is the largest single upgrade in the history of GastroPlus. In this version, we have added three major new capabilities that we expect to expand the use of GastroPlus throughout the pharmaceutical industry and provide new functionality that we believe will attract researchers in environmental toxicology as well."
Dr. Viera Lukacova, team leader for Simulation Technologies at Simulations Plus, said, aVersion 7.0 is the largest single upgrade in the history of GastroPlus. In this version, we have added three major new capabilities that we expect to expand the use of GastroPlus throughout the pharmaceutical industry and provide new functionality that we believe will attract researchers in environmental toxicology as well.a
GastroPlus Version 7.0 now incorporates:
- [ Drug-drug interaction ]
- Ocular drug delivery
- Nasal/pulmonary drug delivery
- Numerous expansions to the basic program and modules for additional user convenience
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: aThe one advantage that some of our competition has had over GastroPlus has been drug-drug interaction. Now, after two years of working with Roche, we have released the most advanced drug-drug interaction capability in the industry. This required a major architectural change to the program, and Dr. Lukacova and her team have done a remarkable job of developing, testing, and documenting this new capability. At the same time, we have added two new market-expanding capabilities for simulating drug delivery to the eye and via nasal/pulmonary passages. We have potential customers working in these areas who have been eagerly waiting for this release. We are expecting additional sales in the very near future as a result of these capabilities. Especially noteworthy is the fact that all three of these new capabilities were developed under funded collaborations with top-five pharmaceutical companies, minimizing our capitalized expenses.a
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Companya™s Words+, Inc., wholly owned subsidiary provides augmentative communication systems and other technologies for persons with disabilities. Simulations Plus is headquartered in Southern California. For more information, visit our web site at [ www.simulations-plus.com ].
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995a" With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like abelieve,a aexpecta and aanticipatea mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.
